Accustem Sciences Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Wendy E. Blosser
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5 Penn Plaza New York City NY United States of America 10001
- IPO Date
- Mar 3, 2022
- CIK
- 0001850767
- Website
- accustem.com
- Similar Companies
- Business
- AccuStem Sciences Inc (OTCQB: ACUT) is a clinical-stage diagnostics company that develops and commercializes genomic tests supporting decision-making across the oncology care continuum, from screening through treatment and monitoring; its lead products include the MicroRNA Signature Classifier (MSC), a 24-microRNA blood test stratifying lung nodules for malignancy risk in low-dose CT screening, and StemPrintER, a 20-gene prognostic assay predicting distant recurrence risk in luminal ER+/HER2-negative early-stage breast cancer patients; the company also offers ancillary services such as hereditary genetic testing and somatic mutation testing to provide comprehensive treatment planning support leveraging tumor stemness biomarkers applicable across tumor types. Founded in 2020 as a spinoff from Tiziana Life Sciences and headquartered in Phoenix, Arizona with operations in the United States and United Kingdom through its wholly owned subsidiary StemPrintER Sciences Limited, AccuStem targets physicians, care teams, and patients at risk of or diagnosed with cancer globally. Recent developments include expanded strategic partnerships with EmeritusDX for blood-based testing infrastructure including Promega Maxwell RSC system installation and a joint product development agreement to commercialize the MSC test targeting 1.6 million annual US lung nodule patients with a planned 2026 launch; a development agreement with Italy's Rete Italiana di Screening Polmonare for MSC validation using clinical trial samples; and multiple open-market share purchases by Board Chairman Gabriele Cerrone increasing his holdings to over 4.9 million shares in 2025.
AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States
AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership
AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer